Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell
• ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
MannKind’s Inhaled Clofazimine Will Advance To An Adaptive Phase 2/3 Study For Potential Treatment Of Rare Lung Disease
Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overcomes systemic toxicity and lessens side effects
Paper published on
MannKind To Rally 57%? Here Are 5 Other Price Target Changes For Wednesday
SVB Leerink raised MannKind Corporation (NASDAQ:MNKD) price target from $5 to $6. . SVB Leerink analyst Thomas Smith…
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
MannKind Shares Fall After Completing Initial Stage Lung Disease Study
MannKind Corporation (NASDAQ: MNKD) has successfully completed a Phase 1 study of clofazimine inhalation suspension (MNKD 101), an inhalation treatment option for nontuberculous mycobacterial (NTM) lung disease.
Mannkind Completes Phase 1 Study of Inhaled Clofazimine; Says ‘Study supports the dosing regimen that will be pursued in further clinical programs’
Study supports the dosing regimen that will be pursued in further clinical programs
No serious adverse events or QT prolongation identified
Planning underway to discuss results and the ongoing clinical
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
UPDATE: FDA Doc For United Therapeutics, MannKind Lung Disease Therapy (Link In Body Of This Headline)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214324s000lbl.pdf
The Daily Biotech Pulse: Pfizer-BioNTech’s COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio’s AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours:
MannKind Q1 EPS $(0.10), Inline, Sales $11.99M Beat $10.58M Estimate
MannKind (NASDAQ:MNKD) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 100 percent decrease over losses of $(0.05) per share from the same period last year. The company